Teleflex Awarded Hemostasis Products Agreements with Premier, Inc.
Teleflex Incorporated (NYSE: TFX) has secured two group purchasing agreements with Premier, Inc., effective July 1, 2024. These agreements, including the Premier National Hemostasis Products and SURPASS® Hemostasis Products agreements, offer Premier members special pricing on Teleflex's hemostatic portfolio. The SURPASS® program aims to achieve best-in-market pricing through aggregated purchasing and standardization.
Teleflex's QuikClot™ Hemostatic Dressings and Devices, which control bleeding faster than standard methods, are now available to Premier members. The portfolio includes products for various hospital departments. The agreements also cover other Teleflex hemostasis products, providing options for different bleeding scenarios in Interventional Cardiology and Radiology.
Teleflex Incorporated (NYSE: TFX) ha firmato due accordi di acquisto di gruppo con Premier, Inc., a partire dal 1° luglio 2024. Questi accordi, tra cui gli accordi sui Prodotti Nazionali per l'Emostasi di Premier e i Prodotti per l'Emostasi SURPASS®, offrono ai membri di Premier prezzi speciali sul portafoglio emostatico di Teleflex. Il programma SURPASS® punta a ottenere i migliori prezzi sul mercato attraverso acquisti aggregati e standardizzazione.
I bendaggi e i dispositivi emostatici QuikClot™ di Teleflex, che controllano il sanguinamento più velocemente dei metodi standard, sono ora disponibili per i membri di Premier. Il portafoglio include prodotti per vari reparti dell'ospedale. Gli accordi coprono anche altri prodotti per l'emostasi di Teleflex, offrendo opzioni per diversi scenari di sanguinamento in Cardiologia Interventistica e Radiologia.
Teleflex Incorporated (NYSE: TFX) ha asegurado dos acuerdos de compra grupal con Premier, Inc., que entrarán en vigor el 1 de julio de 2024. Estos acuerdos, que incluyen los acuerdos sobre Productos Nacionales de Hemostasia de Premier y los Productos de Hemostasia SURPASS®, ofrecen a los miembros de Premier precios especiales en el portafolio hemostático de Teleflex. El programa SURPASS® tiene como objetivo lograr los mejores precios del mercado a través de compras agregadas y estandarización.
Los apósitos y dispositivos hemostáticos QuikClot™ de Teleflex, que controlan el sangrado más rápido que los métodos estándar, ya están disponibles para los miembros de Premier. El portafolio incluye productos para varios departamentos del hospital. Los acuerdos también cubren otros productos de hemostasia de Teleflex, ofreciendo opciones para diferentes escenarios de sangrado en Cardiología Intervencionista y Radiología.
Teleflex Incorporated (NYSE: TFX)는 2024년 7월 1일부터 발효되는 Premier, Inc.와 두 개의 그룹 구매 계약을 체결했습니다. 이 계약에는 Premier의 국가적 지혈 제품 및 SURPASS® 지혈 제품 계약이 포함되어 있으며, Premier 회원에게 Teleflex의 지혈 포트폴리오에 대한 특별 가격을 제공합니다. SURPASS® 프로그램은 집단 구매 및 표준화를 통해 시장 최고의 가격을 달성하는 것을 목표로 합니다.
표준 방법보다 더 빠르게 출혈을 제어하는 Teleflex의 QuikClot™ 지혈 드레싱 및 장치가 이제 Premier 회원에게 제공됩니다. 이 포트폴리오는 다양한 병원 부서를 위한 제품을 포함하고 있습니다. 이 계약은 심혈관 시술 및 방사선학에서 다양한 출혈 시나리오를 위한 옵션을 제공하는 다른 Teleflex 지혈 제품도 포함합니다.
Teleflex Incorporated (NYSE: TFX) a sécurisé deux accords d'achat de groupe avec Premier, Inc., qui entreront en vigueur le 1er juillet 2024. Ces accords, y compris les accords sur les Produits Nationaux d'Hémostase de Premier et les Produits d'Hémostase SURPASS®, offrent aux membres de Premier des prix spéciaux sur le portefeuille hémostatique de Teleflex. Le programme SURPASS® vise à obtenir les meilleurs prix du marché grâce à des achats groupés et à la standardisation.
Les bandages et dispositifs hémostatiques QuikClot™ de Teleflex, qui contrôlent les saignements plus rapidement que les méthodes standards, sont maintenant disponibles pour les membres de Premier. Le portefeuille comprend des produits pour différents départements d'hôpital. Les accords couvrent également d'autres produits d'hémostase de Teleflex, offrant des options pour différents scénarios de saignement en cardiologie interventionnelle et en radiologie.
Teleflex Incorporated (NYSE: TFX) hat zwei Gruppenbeschaffungsverträge mit Premier, Inc. abgeschlossen, die am 1. Juli 2024 in Kraft treten. Diese Verträge, einschließlich der Premier National Hemostasis Products und SURPASS® Hemostasis Products Verträge, bieten den Mitgliedern von Premier Sonderpreise für das hemostatische Portfolio von Teleflex. Das SURPASS®-Programm zielt darauf ab, die besten Marktpreise durch aggregierte Einkäufe und Standardisierung zu erreichen.
Die QuikClot™ hemostatischen Verbände und Geräte von Teleflex, die das Bluten schneller als Standardmethoden kontrollieren, sind jetzt für Premier-Mitglieder verfügbar. Das Portfolio umfasst Produkte für verschiedene Krankenhausabteilungen. Die Verträge decken auch andere hemostatische Produkte von Teleflex ab und bieten Optionen für verschiedene Blutszenarien in der interventionellen Kardiologie und Radiologie.
- Secured two group purchasing agreements with Premier, Inc., potentially increasing sales
- Special pricing for Teleflex products available to Premier's extensive network of 4,350 U.S. hospitals and 300,000 other providers
- Inclusion in Premier's SURPASS® program, which aims for best-in-market pricing through aggregated purchasing
- None.
The announcement of Teleflex's new agreements with Premier, Inc. is a positive development for the company's market position in the healthcare sector. These agreements, particularly the inclusion in Premier's SURPASS® program, could potentially lead to increased sales volume and market share for Teleflex's hemostasis products.
While the financial terms of the agreements are not disclosed, the special pricing and pre-negotiated terms for Premier members suggest a strategic move to capture a larger share of the hemostasis market. The SURPASS® program's focus on aggregated purchasing and standardization across facilities could result in more consistent and potentially higher volume orders for Teleflex.
Investors should note that this agreement covers a diverse portfolio of hemostatic products, including QuikClot™, D-Stat™, Thrombix™ and ThrombiDisc™. This breadth of offerings positions Teleflex well to meet various clinical needs across different hospital departments, potentially driving cross-selling opportunities and increasing overall revenue from Premier's extensive network of approximately 4,350 U.S. hospitals and 300,000 other providers.
However, it's important to consider that the impact on Teleflex's financials will depend on the actual adoption rate among Premier members and the competitive landscape. The healthcare supply market remains highly competitive and other suppliers may seek similar agreements. Investors should monitor future earnings reports to gauge the tangible financial benefits of these agreements.
From a medical perspective, Teleflex's expanded access to Premier's network with its hemostasis products is significant. The QuikClot™ line, which is claimed to control bleeding faster than standard gauze or laparotomy pads, represents an important advancement in acute care settings. This could potentially lead to improved patient outcomes and more efficient emergency care.
The versatility of Teleflex's hemostasis portfolio is noteworthy. Products like D-Stat™ Flowable Hemostat and Thrombix™ Topical Hemostat cater to different clinical scenarios, from abrasions to traumatic injuries. This comprehensive approach aligns well with the varied needs of different hospital departments, potentially increasing adoption rates across Premier's member institutions.
However, it's important to note that while these products show promise, their real-world effectiveness and safety profiles should be continuously monitored. As these products become more widely available through the Premier agreement, there may be opportunities for larger-scale studies to further validate their clinical benefits and cost-effectiveness compared to standard treatments.
The inclusion of silver-containing products like Thrombix™ Topical Hemostat Silver is interesting, given the antimicrobial properties of silver. This could be particularly relevant in settings where infection control is a priority alongside hemostasis.
Overall, this agreement has the potential to enhance the standard of care in bleeding control across a wide range of clinical settings, which could ultimately translate to improved patient outcomes and potentially reduced healthcare costs associated with prolonged bleeding events.
The new agreements between Teleflex and Premier represent a strategic market positioning move in the competitive medical device industry. Premier's extensive network, covering approximately 4,350 U.S. hospitals and 300,000 other providers, offers Teleflex a significant opportunity to expand its market reach and potentially increase its market share in the hemostasis products segment.
The inclusion in Premier's SURPASS® program is particularly noteworthy. This program is designed for Premier's most committed members, suggesting that Teleflex's products could benefit from increased visibility and preferential consideration among a subset of highly engaged healthcare providers. This could lead to more stable and potentially growing demand for Teleflex's hemostasis products.
However, it's important to consider the competitive landscape. While this agreement strengthens Teleflex's position, other major players in the medical device industry likely have or are pursuing similar arrangements. The actual impact on Teleflex's market share will depend on factors such as product performance, pricing competitiveness and the company's ability to leverage this agreement effectively.
The timing of this agreement, starting July 1, 2024, aligns with the ongoing trend of healthcare providers seeking to optimize their supply chains and reduce costs. Teleflex's ability to secure this agreement suggests that their products are perceived as offering good value, which could be a positive indicator for future growth in other markets or with other purchasing organizations.
Investors and market analysts should closely monitor Teleflex's performance in the coming quarters to assess how effectively the company capitalizes on this opportunity and whether it translates into measurable market share gains and revenue growth in the hemostasis product category.
Hemostatic Dressings and Devices are Now Available at Special Pricing for Premier Members
WAYNE, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1, 2024, the Premier National Hemostasis Products and SURPASS® Hemostasis Products agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex products within the hemostatic portfolio.
Premier’s SURPASS® program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier’s most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing.
QuikClot™ Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3 enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab.
“QuikClot™ Hemostatic Dressings and the QuikClot Control+™ Hemostatic Device are critical tools to aid bleeding control and the blood loss mitigation efforts of acute care clinicians,” said Kevin Robinson, President and General Manager, Anesthesia and Emergency Medicine at Teleflex. “We are pleased to support Premier members with these new Hemostasis product agreements and provide clinicians with medical devices that help improve the health and quality of people’s lives.”
The Teleflex hemostasis portfolio also includes D-Stat™ Flowable Hemostat, D-Stat™ Dry Topical Hemostat, Thrombix™ Topical Hemostat, Thrombix™ Topical Hemostat Silver, and ThrombiDisc™ Topical Hemostat. This portfolio provides Interventional Cardiology and Radiology clinicians with options that address their patient’s bleeding scenarios from abrasions to traumatic injuries.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose-driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
References:
1. Causey MW, McVay DP, Miller S, et al. J Scientific Research. 2012; 177 (2): 301-305. Pre-clinical study.
2. Trabattoni D, Montorsi P, Fabbiocchi F, et al. Eur Radiol. 2011; 21: 1687- 1691
3. Data on file at Teleflex. Comparative data may not be indicative of clinical performance.
Rx Only.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
Refer to package insert for complete warnings, indications, contraindications, precautions, potential complications and Instructions For Use.
QuikClot Hemostatic Dressing is intended for use as a topical dressing for local management of bleeding wounds such as cuts, lacerations and abrasions. It may also be used for temporary treatment of severely bleeding wounds such as surgical wounds (operative, postoperative, dermatological, etc.) and traumatic injuries.
The QuikClot Control+™ Hemostatic Device is indicated for temporary control of internal organ space bleeding for patients displaying class III or IV bleeding. It may also be used for control of severely bleeding wounds such as surgical wounds and traumatic injuries.
Cardiac surgical procedures: for temporary control of mild and moderate bleeding in cardiac surgical procedures, as well as in patients displaying class III or class IV bleeding.
Bone surfaces following sternotomy: to control bleeding from bone surfaces following a sternotomy
Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, D-Stat, LMA, Pilling, QuikClot, QuikClot Control+, Rüsch, Thrombix, ThrombiDisc, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2024 Teleflex Incorporated. All rights reserved. MC-009903
Contact:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836
FAQ
What new agreements has Teleflex (TFX) secured with Premier, Inc.?
What products are included in Teleflex's (TFX) hemostasis portfolio under the Premier agreements?
How do Teleflex's (TFX) QuikClot™ Hemostatic Dressings and Devices compare to standard methods?
What is the purpose of Premier's SURPASS® program that Teleflex (TFX) is now part of?
